Which are 5 NZX healthcare stocks to look at ahead of 2022?

Be the First to Comment Read

Which are 5 NZX healthcare stocks to look at ahead of 2022?

 Which are 5 NZX healthcare stocks to look at ahead of 2022?
Image source: metamorworks, Shutterstock.com


  • NZ has obtained 60K courses of Pfizer’s antiviral drug to help people with minor symptoms from becoming very ill.
  • Fisher and Paykel plans to invest in more land and buildings in the next 5 years.
  • Arvida Group delivered an underlying profit of $26.6 million in H1FY22, up 30% on pcp. 

NZ’s Health Minister Andrew Little announced on Monday that NZ had procured supplies of another medicine to deal with COVID-19.

NZ’s drug funding agency Pharmac has obtained 60K courses of an antiviral medicine that can be taken as a tablet and help people with minor symptoms from becoming very sick. The drug works by blocking the split of certain proteins essential to produce a fully active virus.

Pfizer’s anti-viral drug is likely to be delivered to NZ in April once it gets MedSafe’s consent.

On this note, let’s skim through how these 5 NZX healthcare stocks are faring as the year ends.

5 NZX Healthcare Stocks and their financials

Image source: © 2021 Kalkine Media, Data source- Refinitiv

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH;ASX:FPH) 

Fisher and Paykel reported a decline of 2% and 1% in its NPAT and operating revenue in H1 of FY22. However, it reported growth in new applications consumables and Homecare operating revenue.

The Group plans to invest in 3 more manufacturing facilities outside NZ over the next 5 years.

FPH ended the day 1.02% in red to close at $31.95.

Ebos Group Limited (NZX:EBO)

Ebos delivered record FY21 results with increased net profit (+15.5%) and increased dividend payments (+14.2%) to shareholders.

RELATED READ: Which are top 5 NZX healthcare stocks in 2021?

Ebos’ key focus areas will be environmental stewardship, packaging waste, responsible supply chain and quality management.

EBO ended the day 0.28% in green to close at $35.46.

Arvida Group Limited (NZX:ARV)

Arvida's underlying profit for the first half of FY22 was $26.6 million, up 30% over the same period last year. High staff expenses, according to the Group, would be a burden for the industry in the second half of FY22.

RELATED ARTICLE: How are NZX retirement villages stocks doing in December 2021?

Arvida has issued an interim dividend of 2.5cps, which will be paid on 15 December.

ARV ended the day 1.02% in red to close at $1.94.

Pacific Edge Limited (NZX:PEB)

Pacific Edge announced a 66% increase in sales to $66.7 million for the six months ending 30 September 2021 on pcp. During that time, the Group's US sales staff grew from 16 to 28 people.

DO READ: Pacific (NZX:PEB): Does the Company have positive growth outlook for 2022?

With scaled-up activities in the United States and a healthy balance sheet, PEB is well positioned to capitalise on commercial opportunities.

PEB ended the day flat to close at $1.25.

Summerset Group Holdings Limited (NZX:SUMASX:SNZ)

Summerset announced the auction of occupancy rights for the third quarter of 2021. One hundred ninety-nine transactions were completed throughout the quarter, with 117 new purchases and 82 resales, according to the company.

ALSO READ: Why to look at 4 NZX-listed pharma stocks in 2022?

To date, sales have accounted for 95% of full-year sales in 2020.

SUM ended the day 1.24% in green to close at $13.06.

Bottom Line

Eligible Kiwis have achieved a near-85% vaccination rate. Subsequently, the country is now better prepared to tackle new variants of COVID-19.

(NOTE: Currency is reported in NZ Dollar unless stated otherwise)


Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK